Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.

Celldex Therapeutics Inc.

Celldex ( ($CLDX) ) has shared an update. On April 1, 2026, Celldex Therapeutics entered an underwriting agreement with Leerink Partners and TD Sec...

Current Quarter	$-1.1	Next Quarter	$-1.26
Current Year	$-4.95	Next Year	$-5.4
QoQ Growth	-14.5%	YoY Growth	-9.1%
3Y EPS CAGR	-14.3%	Target Price	$55.50
Consensus	Buy	Upside	+65.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CLDX	$33.62	+3.73%	815.38K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CLDX	$33.62	+3.7%	815.38K
3
4
5
6

CLDX

CLDX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Celldex Therapeutics Inc. Data in Excel

Get Celldex Therapeutics Inc. Data in Excel